BRIEF-Amgen and UCB say FDA accepts biologics license application for romosozumab

* Amgen and UCB announce FDA acceptance of biologics license application for romosozumab
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.